Global Semaglutide Market Share 2021 Growth Challenges, Opportunities and Future Trends 2027
The global semaglutide market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). The major factor that is anticipated to drive the growth of the market includes the rise in the incidences of diabetes and obesity across the globe, which is expected to fuel the demand for Semaglutide during the forecast period, as it supports to control blood sugar levels and improves insulin sensitivity. Semaglutide is a glucagon-like peptide (GLP)-one agonist injected into the body. It works by increasing insulin production in response to elevated blood glucose levels while suppressing the excess secretion of glucagon from pancreas alpha cells which also reduces appetite and cravings for food.
The prolific rise in demand
for novel therapies and innovative treatment options, owing to the increasing
prevalence of TZDs has boosted the prospects of the Semaglutide market
substantially. In addition, factors such as a strong product pipeline,
favorable reimbursement policies throughout developed economies have also acted
as a key driving factor that further adds momentum to the successful launch of
these products across different geographies including North America and Europe
regions. Moreover, growing awareness regarding therapeutic benefits offered by
new generation GLP-I agonists has been an added advantage for manufacturers
operating in this space.
To Request a Sample of our Report on Global Semaglutide
Market: https://www.omrglobal.com/request-sample/semaglutide-market
In June 2021, Novo Nordisk A/S declared that the FDA has approved its
diabetes medicine, semaglutide as a weekly 2.4 mg injection for weight
management in people living with obesity. The GLP-1 product will be marketed by
the brand name of Wegovy for chronic weight management in adults with obesity
(initial BMI=30 kg/m2) or overweight (initial BMI=27 kg/m2) with at least one
weight-related comorbidity, such as high blood pressure, type II diabetes, or
high cholesterol.
The approval was based on data from the phase IIIa STEP study, which
enrolled around 4,500 adults with overweight or obesity. Data from the study
showed that people with obesity and without type II diabetes experienced an
average weight loss of 17-18% sustained over 68 weeks. Semaglutide is presently
approved by the trade name of Ozempic as a once-daily pre-filled pen to improve
glycemic control in type II diabetes patients. It was also approved as an oral
tablet by the brand name of Rybelsus in September 2019 in the United States and
is now launched in 15 countries.
Market Coverage
·
The market number available for – 2020-2027
·
Base year- 2020
·
Forecast period- 2021-2027
·
Segment Covered
·
Regions Covered- Globally
·
Competitive Landscape: Novo
Nordisk A/S
(Get 15% Discount on Buying this Report)
A
full Report of Global Semaglutide Market is Available at: https://www.omrglobal.com/industry-reports/semaglutide-market
Global Semaglutide Market Report Segmentation
By Route of Administration
• Oral
• Injection
By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
Global Semaglutide Market by Region
North America
·
United States
·
Canada
Europe
·
UK
·
Germany
·
Spain
·
France
·
Italy
·
Rest of Europe
Asia-Pacific
·
India
·
China
·
Japan
·
South Korea
·
Rest of APAC
Rest of the World
Reasons to buy
from us –
1. We cover more than
15 major industries, further segmented into more than 90 sectors.
2. More than 120
countries are for analysis.
3. Over 100+ paid
data sources mined for investigation.
4. Our expert
research analysts answer all your questions before and after purchasing your
report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company
known for its crisp and concise reports. The company is equipped with an
experienced team of analysts and consultants. OMR offers quality syndicated
research reports, customized research reports, consulting and other
research-based services.
Media
Contact:
Company
Name: Orion Market Research
Contact
Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact
no: +91 7803040404
Comments
Post a Comment